(Q37969833)

26 August 2017

title

Neoadjuvant and adjuvant therapy in relation to surgery for colorectal liver metastases (English)

1 reference

26 August 2017

Antoine Brouquet

1

1 reference

26 August 2017

Bernard Nordlinger

series ordinal

2

1 reference

26 August 2017

publication date

19 December 2011

1 reference

Scandinavian Journal of Gastroenterology

26 August 2017

published in

1 reference

26 August 2017

volume

47

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

286-295

1 reference

Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N99

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Disappearing colorectal liver metastases after chemotherapy: should we be concerned?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Impact of steatosis on perioperative outcome following hepatic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Safe liver resection following chemotherapy for colorectal metastases is a matter of timing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2012.640826

10.3109/00365521.2012.640826

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference